Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19028581 | COMPOSITE BACTERIAL AGENT AND APPLICATION THEREOF | January 2025 | February 2026 | Abandon | 13 | 2 | 0 | No | No |
| 18963644 | BACILLUS PROTEOLYTICUS CWJ-2-GJ AND APPLICATION THEREOF | November 2024 | April 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18946900 | METHOD FOR PRODUCING HYDROGEN GAS FROM SWEET SORGHUM | November 2024 | July 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18886923 | ELECTRO-RESPONSIVE SILK FIBROIN MATERIAL, ELECTRO-RESPONSIVE SILK FIBROIN MICRONEEDLE, INSULIN MICRONEEDLE PATCH HAVING ELECTRO-RESPONSIVE SILK FIBROIN AND PREPARATION METHOD THEREFOR, AND TRANSDERMAL DRUG DELIVERY DEVICE | September 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18717423 | LACTIPLANTIBACILLUS PLANTARUM STRAIN FOR ALLEVIATING HYPERURICEMIA AND COMBINATION AND USE THEREOF | June 2024 | May 2025 | Allow | 11 | 1 | 0 | No | No |
| 18634373 | Triglycerides and Structured Lipids from Short- and Medium-Chain Fatty Acids | April 2024 | August 2025 | Allow | 17 | 1 | 1 | No | No |
| 18593178 | PRODUCTION OF A PROBIOTIC COMPOSITION | March 2024 | March 2026 | Allow | 25 | 2 | 1 | Yes | No |
| 18317511 | ENZYME-ENHANCED ADAMTS-13 ACTIVITY ASSAY | May 2023 | July 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18165127 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF HYDROXYTYROSOL | February 2023 | January 2025 | Abandon | 24 | 2 | 1 | No | No |
| 18163733 | PROBIOTIC STRAIN SELECTED BY TARGETED IN VIVO ENRICHMENT TO AID WITH HEALTHY LACTOSE DIGESTION | February 2023 | May 2025 | Abandon | 28 | 3 | 0 | No | No |
| 18018541 | CONSENSUS SEQUENCE OF THE ANTIGEN TELOMERASE AND THE USE THEREOF IN PREVENTIVE AND THERAPEUTIC VACCINATION | January 2023 | January 2026 | Allow | 36 | 1 | 1 | No | No |
| 18154827 | METHOD FOR PRODUCING PSICOSE 3-EPIMERASE BY HIGH-DENSITY FERMENTATION | January 2023 | May 2024 | Allow | 16 | 2 | 0 | No | No |
| 18083400 | METHODS FOR EVALUATING CANDIDATE THERAPY EFFICACY BASED ON CHANGES IN LYMPHATIC FLUID BIOMARKERS | December 2022 | June 2025 | Allow | 30 | 6 | 1 | Yes | No |
| 18077328 | METHOD FOR PREPARING DIACYLGLYCEROL BY IMMOBILIZED SN-2 LIPASE | December 2022 | July 2024 | Abandon | 19 | 1 | 1 | Yes | No |
| 18070903 | METHOD OF PRECIPITATING PHYTASE | November 2022 | February 2025 | Allow | 26 | 3 | 0 | Yes | No |
| 17998537 | DISCOVERY OF NOVEL AKKERMANSIA MUCINIPHILA AK32 AND APPLICATION THEREOF FOR IMPROVING INTESTINAL FUNCTION | November 2022 | December 2025 | Allow | 38 | 1 | 1 | No | No |
| 18052282 | METHOD FOR CONTROLLING OBESITY BY REGULATING ACTIVITY OF TREK1 | November 2022 | June 2025 | Abandon | 31 | 3 | 1 | Yes | No |
| 17978710 | Triglycerides and Structured Lipids from Short- and Medium-Chain Fatty Acids | November 2022 | August 2024 | Abandon | 22 | 1 | 0 | Yes | No |
| 18049221 | BIOSYNTHETIC PLATFORM FOR THE PRODUCTION OF CANNABINOIDS AND OTHER PRENYLATED COMPOUNDS | October 2022 | August 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17959307 | METHOD FOR REMOVING TBBPA IN WATER, MICROBIAL STRAIN AND MICROBIAL AGENT | October 2022 | December 2025 | Allow | 38 | 1 | 1 | No | No |
| 17881644 | ENZYMATIC SYNTHESIS METHOD OF 1-PALMITIC ACID-2-OLEIC ACID-3-TRIGLYCERIDE STEARATE | August 2022 | April 2025 | Allow | 32 | 1 | 1 | Yes | No |
| 17871833 | Carrier Peptide Fragment for Nucleolar Localization and Use Thereof | July 2022 | November 2023 | Allow | 16 | 0 | 1 | Yes | No |
| 17865099 | CHIMERIC AND OTHER VARIANT BETA-GLUCURONIDASE ENZYMES WITH ENHANCED PROPERTIES | July 2022 | November 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17791502 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION IN BACILLUS LICHENIFORMIS | July 2022 | September 2025 | Allow | 39 | 2 | 0 | Yes | No |
| 17791400 | A PROCESS FOR PRODUCING ALTERNAN-OLIGOSACCHARIDE | July 2022 | November 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17789742 | TNAP LOCALLY ADMINISTERED FOR PROMOTING PERIODONTAL HEALTH | June 2022 | July 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17612345 | MAMMALIAN EXPRESSION VECTORS | June 2022 | February 2026 | Allow | 51 | 2 | 1 | No | No |
| 17830229 | PRODUCTION OF MALONATE SEMIALDEHYDE AND DERIVATIVES BY MICROORGANISMS EXPRESSING ASPARTATE 1-DECARBOXYLASE | June 2022 | July 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17777711 | SUCROSE INVERTASE VARIANTS | May 2022 | February 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 17773736 | MEDICAL COMPOSITIONS AND THEIR USES | May 2022 | April 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17728905 | OYSTER PEPTIDE WITH EFFECT OF IMPROVING SEXUAL FUNCTION AND PREPARATION METHOD THEREOF | April 2022 | May 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17764146 | Agent for Imparting Cool Touch Sensation and Water-Absorbing and Quick-Drying Properties, and Method for Imparting Article with Cool Touch Sensation and Water-Absorbing and Quick-Drying Properties | March 2022 | October 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17762869 | Preparation of Glycosyltransferase UGT76G1 Mutant and Use Thereof | March 2022 | July 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17652832 | BOTULINUM NEUROTOXINS PRODUCTION METHODS | February 2022 | October 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17627018 | PEPTIDE THERAPEUTICS FOR AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES | January 2022 | February 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17625668 | POLYPEPTIDE DIMER WITH HIGH SIALIC ACID CONTENT, COMPRISING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | January 2022 | May 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17597019 | METHOD OF PRODUCING SULFUR-CONTAINING AMINO ACID OR DERIVATIVE THEREOF | December 2021 | September 2024 | Allow | 33 | 1 | 0 | Yes | No |
| 17621957 | DISRUPTION OF CDC42 EFFECTORS IN YEAST FOR INCREASED ALCOHOL AND LYSINE PRODUCTION | December 2021 | March 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17618724 | KETOREDUCTASE MUTANT AND METHOD FOR PRODUCING CHIRAL ALCOHOLS | December 2021 | September 2024 | Allow | 33 | 1 | 0 | No | No |
| 17595460 | PROCESS FOR PREPARING A PEPTIDE SAMPLE | November 2021 | February 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17599752 | A MEDIUM COMPOSITION FOR BOTULINUM TOXIN PRODUCTION BY CULTURING OF CLOSTRIDIUM BOTULINUM | September 2021 | June 2025 | Allow | 44 | 4 | 0 | Yes | No |
| 17479018 | Construction and Application of Engineered Strain of Escherichia Coli for Producing Malic Acid by Fixing CO2 | September 2021 | June 2024 | Allow | 33 | 1 | 0 | Yes | No |
| 17477668 | Double Enzyme Tandem Preparation Method of L-2-Aminobutyric Acid | September 2021 | April 2024 | Allow | 31 | 0 | 0 | Yes | No |
| 17436580 | BACILLUS HALOSACCHAROVORANS STRAIN, COMPOSITION COMPRISING THE SAME, AND USES THEREOF | September 2021 | February 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17402323 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17429198 | BIOTECHNOLOGICAL OPTIMIZATION OF MICROORGANISMS FOR THE 1,2-DEHYDROGENATION OF STEROIDS | August 2021 | January 2026 | Allow | 54 | 3 | 1 | No | No |
| 17427019 | ENGINEERED CELLS FOR IMPROVED PRODUCTION OF CANNABINOIDS | July 2021 | March 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17310154 | DEVICES, SYSTEMS, AND METHODS FOR CONTINUOUS REAL TIME BLOOD CULTURE MEASUREMENT | July 2021 | October 2025 | Allow | 51 | 3 | 0 | No | No |
| 17364755 | INSTRUMENT AND SYSTEM FOR RAPID MICROORGANISM IDENTIFICATION AND ANTIMICROBIAL AGENT SUSCEPTIBILITY TESTING | June 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17417830 | RECOMBINANT YEAST AND METHOD FOR PRODUCING ETHANOL USING SAME | June 2021 | February 2026 | Abandon | 55 | 3 | 1 | No | No |
| 17311099 | IN-LINE PRODUCT CONCENTRATION TO REDUCE VOLUMETRIC LOAD FLOW RATE AND INCREASE PRODUCTIVITY OF A BIND AND ELUTE CHROMATOGRAPHY PURIFICATION | June 2021 | December 2024 | Abandon | 42 | 2 | 0 | No | No |
| 17311106 | GLUCOSE SENSORS AND METHODS OF USE THEREOF | June 2021 | October 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17303092 | METHODS AND SYSTEMS FOR PREPARING AND ANALYZING CELLULAR SAMPLES FOR MORPHOLOGICAL CHARACTERISTICS AND BIOMARKER EXPRESSION | May 2021 | December 2025 | Allow | 55 | 3 | 1 | Yes | No |
| 17263410 | MEMBRANE PROTEIN ACTIVITY MEASUREMENT METHOD | May 2021 | January 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17229355 | SCALABLE FERMENTATION PROCESS | April 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17279441 | METHOD FOR MEASURING BLOOD COAGULATION TIME | March 2021 | September 2025 | Allow | 54 | 3 | 0 | Yes | No |
| 17153471 | Process for Controlled Adsorption and Desorption of Phosphate From Liquids Using Phosphate-Selective Proteins | January 2021 | March 2024 | Allow | 37 | 0 | 1 | No | No |
| 17258252 | BACTERIAL STRAIN FOR RELEASING A RECOMBINANT PROTEIN IN A FERMENTATION METHOD | January 2021 | July 2024 | Allow | 42 | 1 | 1 | No | No |
| 17044726 | ORNITHINE DECARBOXYLASE VARIANT AND METHOD FOR PRODUCING PUTRESCINE BY USING SAME | October 2020 | August 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 16965626 | Method for Manufacturing Protein Fiber | July 2020 | June 2024 | Abandon | 47 | 1 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner MOAZZAMI, NAGHMEH NINA works in Art Unit 1652 and has examined 25 patent applications in our dataset. With an allowance rate of 68.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.
Examiner MOAZZAMI, NAGHMEH NINA's allowance rate of 68.0% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MOAZZAMI, NAGHMEH NINA receive 1.52 office actions before reaching final disposition. This places the examiner in the 27% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MOAZZAMI, NAGHMEH NINA is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +57.1% benefit to allowance rate for applications examined by MOAZZAMI, NAGHMEH NINA. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 37.5% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 16.7% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 11.8% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.